Psilocybin-assisted therapy reduced depression symptoms in a phase 2 trial while highlighting short-term efficacy, safety monitoring, and questions about durability

Psilocybin-assisted therapy is the central focus of this Science DOI page, which appears to concern clinical research on depression and the therapeutic effects of psychedelic treatment. The available identifier strongly suggests a peer-reviewed report tied to psychiatric outcomes, symptom change, and safety evaluation in a controlled medical setting. Psilocybin is commonly studied in combination with psychological support, with researchers tracking depressive symptoms, adverse events, and response durability over follow-up periods. Clinical importance rests on whether benefits emerge rapidly, how long they last, and which patients are most likely to respond. The page is likely a journal landing page rather than a full open summary, so author, publication date, and finer study details are not reliably extractable here without overguessing. The core subject is therapeutic psilocybin research in depression within mainstream biomedical publishing.